Press release
Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference
—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung
About this update from Insmed Incorporated
[{"type":"text","content":"—Data from Retrospective Study Evaluating the Association Between Hospitalization Burden and Delay in Diagnosis of Nontuberculous Mycobacterial (NTM) Lung Disease Among Patients with Chronic Obstructive Pulmonary Disease (COPD) to Be Shared in Oral Presentation—\n—Researchers to Present Subgroup Analysis from Phase 2 WILLOW Study Evaluating Brensocatib Treatment Outcomes by Disease Severity in Patients with Bronchiectasis—\nBRIDGEWATER, N.J., March 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that eight presentations across three of its pillars—ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP)—will be shared at the American Thoracic Society (ATS) 2023 International Conference, taking place May 19-24, 2023, in Washington, D.C.\n\"We are excited to present a broad range of data from our portfolio highlighting critical topics in serious and rare lung diseases, including real-world ARIKAYCE and NTM lung disease data as well as subgroup analyses from the Phase 2 WILLOW study of brensocatib in bronchiectasis,\" said Martina Flammer, M.D., M.B.A, Chief Medical Officer of Insmed. \"We look forward to engaging with the scientific community at ATS as we work together to address the burden on patients, their providers, and the healthcare system.\"\nPresentations:\nPoster discussion session, Monday, May 22, 9:00 AM-11:00 AM ET: A Qualitative Interview Study to Explore the Use of Adverse Event Mitigation Strategies Among Adults Receiving Amikacin Liposome Inhalation Suspension (ALIS) in Real World Settings (B28/920)Thematic poster session, Monday, May 22, 9:00 AM–4:15 PM ET: Treprostinil Palmitil Hydrolysis Is Facilitated by Lung Esterases (B59/P218)Mini symposium, Monday, May 22, 2:15 PM-4:15 PM ET: Long-term Hospitalization Burden Among Patients With Chronic Obstructive Pulmonary Disease With Possible Diagnostic Delays of Nontuberculous Mycobacterial Lung Disease (B98)Poster discussion session, Monday, May 22, 2:15 PM-4:15 PM ET:Outcomes of Patients With Bronchiectasis by Disease Severity: Subgroup Analysis From the Brensocatib WILLOW Study (B103/808)The Dipeptidyl Peptidase-1 Inhibitor Brensocatib Reduces Airway Azurocidin-1 Leve...